Pancreatic cancer is among the most aggressive cancer types, with survival rates being very low and current treatment being ...

Inhibiting transient receptor potential melastatin 2 (TRPM2) may mitigate injury arising from ischemic stroke. Researchers at ...

Raqualia Pharma Inc.’s Fimecs Inc. subsidiary has agreed with Astellas Pharma Inc. to add two new targets under their ongoing ...

Kedrion SpA’s investigational plasma-derived treatment for congenital aceruloplasminemia has been awarded European orphan ...

Researchers from Stanford University have reported that inhibiting the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) ...

CSPC Pharmaceutical Group Ltd. has gained clinical trial clearance from China’s National Medical Products Administration ...

In an effort to develop more effective estrogen receptor α (ERα) inhibitors, researchers at Nanjing University of Chinese ...

Eli Lilly & Co. has synthesized relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of pulmonary hypertension, chronic obstructive pulmonary disease, acute kidney disease ...

SK Biopharmaceuticals Co. Ltd. has signed a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire ...

Boehringer Ingelheim Pharma GmbH & Co. KG has described cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoinflammatory interferonopathy, idiopathic ...

Kymera Therapeutics Inc. has disclosed signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, cardiovascular ...

Researchers from the Medical School of Nanjing University hypothesized that in ulcerative colitis, the gut-resident macrophages may be compromised, leading to impaired integrity of the epithelial ...